Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (974)	4/4/1998 2:10:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Click here to read a summary of the Viagra article featured in the 3/30/98 issue of the FDC Reports "Pink Sheets"- an industry newsletter. fdcreports.com Other highlights include: -FDA reviewers remarked that the size of trials, which were similar to development programs for widely used products like antihypertensives, adds comfort to the approval decision. -Viagra shows efficacy in a wide range of subgroups of patients with male erectile dysfunction. -Viagra's patent expires June 18, 2011. - Most significant side effects were headache (16% vs 4% placebo), flushing (10% vs 1% placebo) and dyspepsia (upset stomach) (7% vs 2% placebo). 3% of patients reported visual disturbances, described as color tinge or light sensitivity -Viagra is contraindicated in patients taking nitrates...estimated at approximately 5% of ED patients. Have PFun! BigKNY3